Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Director | June 30, 2026 | July 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date June 30, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 416,742 |
Reported balance
After 2026-06-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-30 · Grant · Acquired 268 · Balance 416,742 F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c). F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c).
F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2018 Filed Jun 7, 2018 00:12 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 28,150 | $30.34 | $854,071.00 |
DisclosureSEC source: 0001209191-18-036187 · doc4.xml · nonDerivative · entry 3 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,314 F3 · price: On June 4, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 28,150 shares in multiple trades at prices ranging from $30.00 to $30.95. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 04, 2018 Filed Jun 7, 2018 00:12 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 26,782 | $29.31 | $784,980.42 |
DisclosureSEC source: 0001209191-18-036187 · doc4.xml · nonDerivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,464 F2 · price: On June 4, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 26,782 shares in multiple trades at prices ranging from $29.00 to $29.95. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 04, 2018 Filed Jun 7, 2018 00:12 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 149,878 | $28.43 | $4,261,031.54 |
DisclosureSEC source: 0001209191-18-036187 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,246 F1 · price: On June 4, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 149,878 shares in multiple trades at prices ranging from $28.00 to $28.95. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 21:16 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Stock Unit · Derivative | 27,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-014987 · doc4.xml · derivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,778 Underlying: Ordinary Shares · 27,778 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one (1) ordinary share. F3 · derivative.exercise_date: One-third of these restricted stock units are scheduled to vest on each of February 27, 2019, 2020 and 2021, subject to the reporting person's continued employment through such dates. F3 · derivative.expiration_date: One-third of these restricted stock units are scheduled to vest on each of February 27, 2019, 2020 and 2021, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 21:16 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 202,758 | $0.00 Strike: $21.15 | $0.00 |
DisclosureSEC source: 0001209191-18-014987 · doc4.xml · derivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,758 Underlying: Ordinary Shares · 202,758 shares Expires 2028-02-27 F1 · derivative.exercise_date: Options to buy 202,758 ordinary shares will vest and become exercisable in equal installments on each of February 27, 2019, 2020, 2021 and 2022, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 22, 2018 Filed Feb 26, 2018 22:11 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 53,334 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-013427 · doc4.xml · derivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,666 Underlying: Ordinary Shares · 53,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| February 22, 2018 Filed Feb 26, 2018 22:11 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 53,334 | $21.55 | $1,149,347.70 |
DisclosureSEC source: 0001209191-18-013427 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,124 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 21:22 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 13,974 | $24.02 | $335,588.40 |
DisclosureSEC source: 0001209191-18-006207 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,790 F1 · shares: On January 29, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 13,974 shares in multiple trades at prices ranging from $24.00 to $24.10. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 25, 2018 Filed Jan 26, 2018 21:14 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 6,456 | $22.43 | $144,839.71 |
DisclosureSEC source: 0001209191-18-005555 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 370,764 F1 · shares: On January 25, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 6,456 shares in multiple trades at prices ranging from $22.00 to $22.75. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 24, 2018 Filed Jan 25, 2018 21:26 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 10,600 | $22.17 | $235,007.30 |
DisclosureSEC source: 0001209191-18-005377 · doc4.xml · nonDerivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,220 F2 · shares: On January 24, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 10,600 shares in multiple trades at prices ranging from $22.00 to $22.45. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 21:26 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 10,248 | $22.03 | $225,794.18 |
DisclosureSEC source: 0001209191-18-005377 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 387,820 F1 · shares: On January 23, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 10,248 shares in multiple trades at prices ranging from $22.00 to $22.15. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 16, 2018 Filed Jan 17, 2018 22:05 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 14,900 | $22.20 | $330,754.67 |
DisclosureSEC source: 0001209191-18-004010 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,068 F1 · price: On January 16, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 14,900 shares in multiple trades at prices ranging from $22.00 to $22.50. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 12, 2018 Filed Jan 16, 2018 22:00 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 22,895 | $22.02 | $504,237.19 |
DisclosureSEC source: 0001209191-18-003626 · doc4.xml · nonDerivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,968 F2 · price: On January 12, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 22,895 shares in multiple trades at prices ranging from $22.00 to $22.10. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 11, 2018 Filed Jan 16, 2018 22:00 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 313,525 | $22.35 | $7,007,503.22 |
DisclosureSEC source: 0001209191-18-003626 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 435,863 F1 · price: On January 11, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 313,525 shares in multiple trades at prices ranging from $22.00 to $22.85. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 08, 2018 Filed Jan 10, 2018 21:06 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 283 | $15.05 | $4,257.74 |
DisclosureSEC source: 0001209191-18-003111 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 749,388 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2017 through December 31, 2017. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 3, 2017. Read SEC document |
| November 06, 2017 Filed Nov 8, 2017 21:14 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 6,919 | $22.00 | $152,218.00 |
DisclosureSEC source: 0001209191-17-059740 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 749,105 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| November 03, 2017 Filed Nov 6, 2017 21:15 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,300 | $22.00 | $50,600.00 |
DisclosureSEC source: 0001209191-17-059400 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 756,024 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| November 01, 2017 Filed Nov 2, 2017 20:20 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 15,716 | $22.01 | $345,869.87 |
DisclosureSEC source: 0001209191-17-058842 · doc4.xml · nonDerivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 758,324 F2 · price: On November 1, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 15,716 shares in multiple trades at prices ranging from $22.00 to $22.05. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 31, 2017 Filed Nov 2, 2017 20:20 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 150 | $22.00 | $3,300.00 |
DisclosureSEC source: 0001209191-17-058842 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 774,040 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| September 25, 2017 Filed Sep 27, 2017 20:18 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 900 | $22.05 | $19,845.00 |
DisclosureSEC source: 0001209191-17-054125 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 774,190 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| September 14, 2017 Filed Sep 15, 2017 20:05 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,772 | $22.00 | $38,984.00 |
DisclosureSEC source: 0001209191-17-052951 · doc4.xml · nonDerivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 775,090 Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 20:05 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 35,500 | $22.01 | $781,518.30 |
DisclosureSEC source: 0001209191-17-052951 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 776,862 F1 · price: On September 13, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 35,500 shares in multiple trades at prices ranging from $22.00 to $22.10. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 14, 2017 Filed Jul 18, 2017 20:48 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 354,780 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001209191-17-045514 · doc4.xml · derivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 354,780 shares Expires 2020-10-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested and currently exercisable as of the date hereof. Read SEC document |
| July 14, 2017 Filed Jul 18, 2017 20:48 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 354,780 | $0.38 | $134,816.40 |
DisclosureSEC source: 0001209191-17-045514 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 812,362 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 11, 2017 Filed Jul 13, 2017 20:14 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 5,183 | $20.19 | $104,644.77 |
DisclosureSEC source: 0001209191-17-045037 · doc4.xml · nonDerivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 457,582 F2 · price: On July 11, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 5,183 shares in multiple trades at prices ranging from $19.80 to $20.75. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 11, 2017 Filed Jul 13, 2017 20:14 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,200 | $19.40 | $42,680.00 |
DisclosureSEC source: 0001209191-17-045037 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 462,765 F1 · price: On July 11, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 2,200 shares in multiple trades at prices ranging from $18.80 to $19.75. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 10, 2017 Filed Jul 11, 2017 20:22 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 203,900 | $18.08 | $3,685,900.30 |
DisclosureSEC source: 0001209191-17-044773 · doc4.xml · nonDerivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 464,965 F2 · price: On July 10, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 203,900 shares in multiple trades at prices ranging from $18.00 to $18.25. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 07, 2017 Filed Jul 11, 2017 20:22 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 70,459 | $18.03 | $1,270,657.61 |
DisclosureSEC source: 0001209191-17-044773 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 668,865 F1 · price: On July 7, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 70,459 shares in multiple trades at prices ranging from $18.00 to $18.15. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 06, 2017 Filed Jul 7, 2017 20:33 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 5,050 | $18.09 | $91,344.40 |
DisclosureSEC source: 0001209191-17-044389 · doc4.xml · nonDerivative · entry 3 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 739,324 F4 · price: On July 6, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 5,050 shares in multiple trades at prices ranging from $18.00 to $18.20. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 20:33 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 155,088 | $18.14 | $2,813,916.67 |
DisclosureSEC source: 0001209191-17-044389 · doc4.xml · nonDerivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 744,374 F3 · price: On July 5, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 155,088 shares in multiple trades at prices ranging from $18.00 to $18.35. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 20:33 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 2,545 | $6.67 | $16,982.79 |
DisclosureSEC source: 0001209191-17-044389 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 899,462 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2017 through June 30, 2017. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 3, 2017. Read SEC document |
| June 19, 2017 Filed Jun 21, 2017 20:17 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 124,720 | $15.51 | $1,934,906.08 |
DisclosureSEC source: 0001209191-17-041200 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 896,917 F1 · price: On June 19, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 124,720 shares in multiple trades at prices ranging from $15.00 to $15.85. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 16, 2017 Filed Jun 19, 2017 20:31 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 9,212 | $15.02 | $138,345.82 |
DisclosureSEC source: 0001209191-17-040831 · doc4.xml · nonDerivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,021,637 F2 · price: On June 16, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 9,212 shares in multiple trades at prices ranging from $15.00 to $15.10. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 20:31 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 33,245 | $15.19 | $504,891.82 |
DisclosureSEC source: 0001209191-17-040831 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,030,849 F1 · price: On June 15, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 33,245 shares in multiple trades at prices ranging from $15.00 to $15.45. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 14, 2017 Filed Jun 15, 2017 20:17 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 5,402 | $15.01 | $81,067.81 |
DisclosureSEC source: 0001209191-17-040115 · doc4.xml · nonDerivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,064,094 F2 · price: On June 14, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 5,402 shares in multiple trades at prices ranging from $15.00 to $15.05. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 20:17 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 88,700 | $15.23 | $1,351,078.40 |
DisclosureSEC source: 0001209191-17-040115 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,069,496 F1 · price: On June 13, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 88,700 shares in multiple trades at prices ranging from $15.00 to $15.475. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 12, 2017 Filed Jun 13, 2017 22:35 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 5,100 | $15.09 | $76,933.50 |
DisclosureSEC source: 0001209191-17-039667 · doc4.xml · nonDerivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,158,196 F2 · price: On June 12, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 5,100 shares in multiple trades at prices ranging from $15.00 to $15.25. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 09, 2017 Filed Jun 13, 2017 22:35 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 175,501 | $15.13 | $2,654,979.13 |
DisclosureSEC source: 0001209191-17-039667 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,163,296 F1 · price: On June 9, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 175,501 shares in multiple trades at prices ranging from $15.00 to $15.30. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 21:06 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 342,954 | $0.00 Strike: $0.17 | $0.00 |
DisclosureSEC source: 0000899243-17-005561 · doc4.xml · derivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 342,954 shares Expires 2017-03-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested and currently exercisable as of the date hereof. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 21:06 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 342,954 | $0.17 | $58,302.18 |
DisclosureSEC source: 0000899243-17-005561 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,338,797 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 21:05 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Stock Unit · Derivative | 160,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-005219 · doc4.xml · derivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Ordinary Shares · 160,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one (1) ordinary share. F3 · derivative.exercise_date: One-third of these restricted stock units are scheduled to vest on each of February 22, 2018, February 22, 2019, and February 22, 2020, subject to Mr. Danziger's continued employment through such dates. F3 · derivative.expiration_date: One-third of these restricted stock units are scheduled to vest on each of February 22, 2018, February 22, 2019, and February 22, 2020, subject to Mr. Danziger's continued employment through such dates. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 21:05 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 375,000 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0000899243-17-005219 · doc4.xml · derivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,000 Underlying: Ordinary Shares · 375,000 shares Expires 2027-02-22 F1 · derivative.exercise_date: Options to buy 375,000 ordinary shares will vest and become exercisable in equal installments on each of February 22, 2018, 2019, 2020 and 2021, subject to Mr. Danziger's continued employment through such dates. Read SEC document |
| January 06, 2017 Filed Jan 6, 2017 21:05 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 3,156 | $6.67 | $21,059.99 |
DisclosureSEC source: 0000899243-17-000670 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 995,843 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of August 1, 2016 through December 31, 2016. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on December 30, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.